Biogen, Orphan Biovitrum Announce Positive ALPROLIX, ELOCTATE Phase 3 Data Across Multiple Hemophilia Populations at ASH

Today Biogen Idec BIIB and Swedish Orphan Biovitrum AB (publ) (Sobi) SOBI announced new results from Phase 3 studies of their investigational long-lasting recombinant factor IX and VIII Fc fusion protein candidates for hemophilia B and A, ALPROLIXTM and ELOCTATETM, including an interim analysis of pediatric pharmacokinetics (PK) data. These interim data are the first to demonstrate that ALPROLIX and ELOCTATE have consistently prolonged half-lives (a measure of the time therapy circulates in the bloodstream) in children, compared to study participants' prior therapies. Investigators presented these results, which were consistent with PK results in adults and adolescents, at the 55th Annual Meeting of the American Society of Hematology (ASH) in New See full press release